Genmab — Oktober 2024

[E_L]

sorry, i stand corrected, misread the question, approved 2L+, not yet in first line

[E_L]

i think innovaTV 207 also ahs an arm for first line head an neck even if i am not mistaken lahn? (next to
2L+

[E_L]

Genmab indgår partnerskab med amerikansk kræftfirma

-Revitope Oncology https://medwatch.dk/Medicinal___Biotek/article17585749.ece

[lahn1]

Yes innovaTV207 arm F and G respectively Tivdak+Ketruda and the same + carboplatin i 1L SCCHN

[E_L]

ok. i assume we'll hear about plans for a potential new Ph3 trial next week, as the goal was to start it in 2024...

[lahn1]

on the last investor call my impression from Jan was that he would want to go ahead in with. ph3 but pending on PFE. But Tox is very high so maybe..... as you said minutes ago reg. Profound

[lahn1]

Hvad sker der med Gen1046. Udskudt 12 mdr. Ny tekst siger at, The average trial duration for an individual subject will be about 74 weeks. 17,6 mdr. som vi så på ASCO. Så tror v det overraskende gode OS holder ?. Hvad siger 21 weeks treatment duration os ? fortæller et noget om median DoR ? som ikke var nået på ASCO

[Solsen]

We can expect new trials with ADCs from the M&A - this is hot in the sector. T-cell engager is aæso

[Solsen]

…also hot. I had listened to a call where the KOLs said that we have come to a plateau in treating solid cancers. ADCs and T-cell engagers was mentioned as exsamples where new progress could come.

[Stroka]

God morgen

[ProinvestorNEWS]

Genmab licenses Revitope's dual-antigen T-cell tech in $600M+ deal https://firstwordpharma.com/story/5907650

[LP90]

Godmorgen

[E_L]

Revitope press release - Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology https://www.prnewswire.com/news-releases/revitope-enters-into-a-license-agreement-for-next-generation-t-cell-engagement-technology-302290430.html?utm_source=dlvr.it&utm_medium=twitter

[E_L]

novartis q3-2024-earnings-call-transcript https://www.fool.com/earnings/call-transcripts/2024/10/29/novartis-ag-nvs-q3-2024-earnings-call-transcript/ Kesimpta -We're annualizing now well above $3 billion, and have the opportunity, I think, to well exceed our $4 billion peak sales guidance to date.

[StockBull]

EL 15.12: seems they have been working on this since 2021. Are part 1 completed and now part 2 . https://institut-curie.org/clinical-trial/gct1047-01

[StockBull]

8 Super Gems Found, Out of 100+ Stocks (Quality + Hyper Growth + Deep Value + High Cashflow) https://www.youtube.com/watch?v=ude3-6H8GtM

[E_L]

But they stopped recruiting. it is possible they'll get all the data they need to proceed with the 179 patients currently recruited, but i doubt that. But would very much like to hear that i am wrong here next week.

[StockBull]

It seems they haven't fully integrated the AI technology that was anticipated to streamline processes.

[StockBull]

Probably its only on future trials. Wonder if they can use less patients now that they use AI

[StockBull]

Implementeringen af AI i kliniske forsøg kan faktisk påvirke rekrutteringsstrategierne for patienter. AI-teknologier kan muligvis strømline processer, forbedre målretning af patienter eller forbedre dataanalyse, hvilket potentielt kan føre til mere effektiv rekruttering.